These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9727891)

  • 1. Troglitazone use in insulin-treated type 2 diabetic patients. The Troglitazone Insulin Study Group.
    Buse JB; Gumbiner B; Mathias NP; Nelson DM; Faja BW; Whitcomb RW
    Diabetes Care; 1998 Sep; 21(9):1455-61. PubMed ID: 9727891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.
    Fonseca VA; Valiquett TR; Huang SM; Ghazzi MN; Whitcomb RW
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3169-76. PubMed ID: 9745421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients.
    Fonseca V; Foyt HL; Shen K; Whitcomb R
    Diabetes Care; 2000 Mar; 23(3):354-9. PubMed ID: 10868865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
    Schwartz S; Raskin P; Fonseca V; Graveline JF
    N Engl J Med; 1998 Mar; 338(13):861-6. PubMed ID: 9516220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
    Kumar S; Boulton AJ; Beck-Nielsen H; Berthezene F; Muggeo M; Persson B; Spinas GA; Donoghue S; Lettis S; Stewart-Long P
    Diabetologia; 1996 Jun; 39(6):701-9. PubMed ID: 8781766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes.
    Ebeling P; Teppo AM; Koistinen HA; Viikari J; Rönnemaa T; Nissén M; Bergkulla S; Salmela P; Saltevo J; Koivisto VA
    Diabetologia; 1999 Dec; 42(12):1433-8. PubMed ID: 10651262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
    Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
    Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.
    Horton ES; Whitehouse F; Ghazzi MN; Venable TC; Whitcomb RW
    Diabetes Care; 1998 Sep; 21(9):1462-9. PubMed ID: 9727892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
    Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
    Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
    Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
    Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy.
    Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
    Diabetes Care; 1996 Feb; 19(2):151-6. PubMed ID: 8718436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
    Hershon KS; Hershon PM
    Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
    Raskin P; Jovanovic L; Berger S; Schwartz S; Woo V; Ratner R
    Diabetes Care; 2000 Jul; 23(7):979-83. PubMed ID: 10895850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
    Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
    Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes.
    Sironi AM; Vichi S; Gastaldelli A; Pecori N; Anichini R; Foot E; Seghieri G; Ferrannini E
    Clin Pharmacol Ther; 1997 Aug; 62(2):194-202. PubMed ID: 9284856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
    Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
    Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing the dose response curve for metabolic control with troglitazone, an insulin action enhancer, in type 2 diabetes patients.
    Young MA; Eckland DJ; Eastmond R; Lettis S
    Ann Med; 1998 Apr; 30(2):206-12. PubMed ID: 9667800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.
    Antonucci T; Whitcomb R; McLain R; Lockwood D; Norris RM
    Diabetes Care; 1997 Feb; 20(2):188-93. PubMed ID: 9118772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus.
    Maruyama S; Yanagisawa K; Kanamuro R; Teno S; Iwamoto Y
    Diabetes Res Clin Pract; 2001 Sep; 53(3):161-4. PubMed ID: 11483231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.
    Kato K; Yamada D; Midorikawa S; Sato W; Watanabe T
    Metabolism; 2000 May; 49(5):662-5. PubMed ID: 10831180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.